Validated QPS Assays
The vast majority of today’s modern bioanalytical methods for pharmacokinetics, pharmacodynamics, and immunogenicity assessment are based on mass spectrometry and/or immuno-bioanalytical approaches. However, for a small but important number of compounds, LC MS/MS or LBA are less than satisfactory. A good alternative is Inductively Coupled Plasma Mass Spectrometry (ICP-MS). In ICP MS, the samples are ionized by an inductively coupled plasma (ionization source) and the ions of interest are separated, detected, and quantitated by a mass spectrometer.
The QPS Assay Finder contains a broad range of validated assays for all of your bioanalytical needs.
Search For An Assay Here
Atazanavir (ATV)
| Matrix: | Human Plasma |
| Assay Range: | 20 - 8,000 ng/mL |
| Sample Volume: | 0.05 mL |
| Anti-Coagulant: | EDTA |
| Storage Temperature (°C): | -20 & -70 |
| Platform: | LC-MS/MS |
| Site: | QPS-India |
| CLIA: | No |
| Therapy Area: | Antiviral - HIV |
| Classification: | Drugs |
Atazanavir (ATV)
| Matrix: | Human Plasma |
| Assay Range: | 0.01 - 5 ng/mL |
| Sample Volume: | 0.05 mL |
| Anti-Coagulant: | EDTA |
| Storage Temperature (°C): | -70 |
| Platform: | LC-MS/MS |
| Site: | QPS-Delaware |
| CLIA: | No |
| Therapy Area: | Antiviral - HIV |
| Classification: | Drugs |
Atomoxetine
| Matrix: | Human Plasma |
| Assay Range: | 5 - 2,500 ng/mL |
| Sample Volume: | 0.05 mL |
| Anti-Coagulant: | EDTA |
| Storage Temperature (°C): | -20 & -70 |
| Platform: | LC-MS/MS |
| Site: | QPS-India |
| CLIA: | No |
| Therapy Area: | ADHD |
| Classification: | Drugs |
Atorvastatin
o-atorvastatin
p-atorvastatin
| Matrix: | Human Plasma |
| Assay Range: | 0.4 - 400 ng/mL 0.2 - 200 ng/mL 0.06 - 60 ng/mL |
| Sample Volume: | 0.3 mL |
| Anti-Coagulant: | EDTA |
| Storage Temperature (°C): | -20 & -70 |
| Platform: | LC-MS/MS |
| Site: | QPS-India |
| CLIA: | No |
| Therapy Area: | Cardiovascular |
| Classification: | Drugs |
Atorvastatin
o-atorvastatin
p-atorvastatin
| Matrix: | Human Plasma |
| Assay Range: | 0.1 - 150 ng/mL 0.1 - 150 ng/mL 0.05 - 15 ng/mL |
| Sample Volume: | 0.5 mL |
| Anti-Coagulant: | EDTA |
| Storage Temperature (°C): | -20 & -70 |
| Platform: | LC-MS/MS |
| Site: | QPS-India |
| CLIA: | No |
| Therapy Area: | Cardiovascular |
| Classification: | Drugs |
Atorvastatin
o-atorvastatin
p-atorvastatin
| Matrix: | Human Plasma |
| Assay Range: | 1.00 - 500 ng/mL |
| Sample Volume: | 0.05 mL |
| Anti-Coagulant: | EDTA |
| Storage Temperature (°C): | -20 |
| Platform: | LC-MS/MS |
| Site: | QPS-NL |
| CLIA: | No |
| Therapy Area: | Cardiovascular |
| Classification: | Drugs |
Atorvastatin
o-atorvastatin
p-atorvastatin
| Matrix: | Human Plasma |
| Assay Range: | 0.1 - 100 ng/mL |
| Sample Volume: | 0.1 mL |
| Anti-Coagulant: | EDTA |
| Storage Temperature (°C): | -70 |
| Platform: | LC-MS/MS |
| Site: | QPS-Delaware |
| CLIA: | No |
| Therapy Area: | Cardiovascular |
| Classification: | Drugs |
Atorvastatin
| Matrix: | Human Plasma |
| Assay Range: | 0.1 - 25 ng/mL |
| Sample Volume: | 0.4 mL |
| Anti-Coagulant: | EDTA |
| Storage Temperature (°C): | -20 & -70 |
| Platform: | LC-MS/MS |
| Site: | QPS-India |
| CLIA: | No |
| Therapy Area: | Cardiovascular |
| Classification: | Drugs |
Axitinib
| Matrix: | Human Plasma |
| Assay Range: | 0.1 - 120 ng/mL |
| Sample Volume: | 0.2 mL |
| Anti-Coagulant: | EDTA |
| Storage Temperature (°C): | -20 & -70 |
| Platform: | LC-MS/MS |
| Site: | QPS-India |
| CLIA: | No |
| Therapy Area: | Oncology |
| Classification: | Drugs |
Axitinib
| Matrix: | Human Serum |
| Assay Range: | 0.1 - 100 ng/mL |
| Sample Volume: | 0.1 mL |
| Anti-Coagulant: | N/A |
| Storage Temperature (°C): | -70 |
| Platform: | LC-MS/MS |
| Site: | QPS-Delaware |
| CLIA: | No |
| Therapy Area: | Oncology |
| Classification: | Drugs |
Azilsartan
| Matrix: | Human Plasma |
| Assay Range: | 20 - 10,000 ng/mL |
| Sample Volume: | 0.2 mL |
| Anti-Coagulant: | EDTA |
| Storage Temperature (°C): | -20 & -70 |
| Platform: | LC-MS/MS |
| Site: | QPS-India |
| CLIA: | No |
| Therapy Area: | Cardiovascular |
| Classification: | Drugs |
Azithromycin
| Matrix: | Human Plasma |
| Assay Range: | 2 - 400 ng/mL |
| Sample Volume: | 0.2 mL |
| Anti-Coagulant: | EDTA |
| Storage Temperature (°C): | -20 |
| Platform: | LC-MS/MS |
| Site: | QPS-Taiwan |
| CLIA: | No |
| Therapy Area: | Antibiotic |
| Classification: | Drugs |
Azithromycin
| Matrix: | Human Plasma |
| Assay Range: | 0.5 - 500 ng/mL |
| Sample Volume: | 0.05 mL |
| Anti-Coagulant: | EDTA |
| Storage Temperature (°C): | -20 & -70 |
| Platform: | LC-MS/MS |
| Site: | QPS-Delaware |
| CLIA: | No |
| Therapy Area: | Antibiotic |
| Classification: | Drugs |
Benazepril
Benazeprilat
| Matrix: | Human Plasma |
| Assay Range: | 1 - 1,000 ng/mL |
| Sample Volume: | 0.1 mL |
| Anti-Coagulant: | EDTA |
| Storage Temperature (°C): | -20 |
| Platform: | LC-MS/MS |
| Site: | QPS-Delaware |
| CLIA: | No |
| Therapy Area: | Cardiovascular |
| Classification: | Drugs |
Benidipine
| Matrix: | Human Plasma |
| Assay Range: | 0.025 - 2.5 ng/mL |
| Sample Volume: | 0.2 mL |
| Anti-Coagulant: | Heparin |
| Storage Temperature (°C): | -20 |
| Platform: | LC-MS/MS |
| Site: | QPS-Taiwan |
| CLIA: | No |
| Therapy Area: | Cardiovascular |
| Classification: | Drugs |
Bevacizumab (ADA)
| Matrix: | Human Serum |
| Assay Range: | N/A |
| Sample Volume: | 0.01 mL |
| Anti-Coagulant: | N/A |
| Storage Temperature (°C): | -70 |
| Platform: | ECL (MSD) |
| Site: | QPS-Delaware |
| CLIA: | No |
| Therapy Area: | Oncology |
| Classification: | Drugs |
Bevacizumab (PK)
| Matrix: | Human Serum |
| Assay Range: | 250 - 3,000 ng/mL |
| Sample Volume: | 0.03 mL |
| Anti-Coagulant: | N/A |
| Storage Temperature (°C): | -70 |
| Platform: | ELISA |
| Site: | QPS-Delaware |
| CLIA: | No |
| Therapy Area: | Oncology |
| Classification: | Drugs |
Bicalutamide
| Matrix: | Human Plasma |
| Assay Range: | 20 - 3,000 ng/mL |
| Sample Volume: | 0.1 mL |
| Anti-Coagulant: | EDTA |
| Storage Temperature (°C): | -20 & -70 |
| Platform: | LC-MS/MS |
| Site: | QPS-India |
| CLIA: | No |
| Therapy Area: | Oncology |
| Classification: | Drugs |
Bilastine
| Matrix: | Human Plasma |
| Assay Range: | 2 - 600 ng/mL |
| Sample Volume: | 0.1 mL |
| Anti-Coagulant: | EDTA |
| Storage Temperature (°C): | -20 & -70 |
| Platform: | LC-MS/MS |
| Site: | QPS-India |
| CLIA: | No |
| Therapy Area: | Antihistamine |
| Classification: | Drugs |
Bisoprolol
| Matrix: | Human Plasma |
| Assay Range: | 0.2 - 120 ng/mL |
| Sample Volume: | 0.2 mL |
| Anti-Coagulant: | EDTA |
| Storage Temperature (°C): | -20 & -70 |
| Platform: | LC-MS/MS |
| Site: | QPS-India |
| CLIA: | No |
| Therapy Area: | Cardiovascular |
| Classification: | Drugs |
Bisoprolol
| Matrix: | Human Plasma |
| Assay Range: | 0.2 - 30 ng/mL |
| Sample Volume: | 0.2 mL |
| Anti-Coagulant: | Heparin |
| Storage Temperature (°C): | -20 |
| Platform: | LC-MS/MS |
| Site: | QPS-Taiwan |
| CLIA: | No |
| Therapy Area: | Cardiovascular |
| Classification: | Drugs |
Bortezomib
| Matrix: | Human Plasma |
| Assay Range: | 0.5 - 500 ng/mL |
| Sample Volume: | 0.3 mL |
| Anti-Coagulant: | EDTA |
| Storage Temperature (°C): | -20 & -70 |
| Platform: | LC-MS/MS |
| Site: | QPS-India |
| CLIA: | No |
| Therapy Area: | Oncology |
| Classification: | Drugs |
Bortezomib
| Matrix: | Human Plasma |
| Assay Range: | 0.1 - 100 ng/mL |
| Sample Volume: | 0.2 mL |
| Anti-Coagulant: | EDTA |
| Storage Temperature (°C): | -20 & -70 |
| Platform: | LC-MS/MS |
| Site: | QPS-India |
| CLIA: | No |
| Therapy Area: | Oncology |
| Classification: | Drugs |
Bosentan
Sitaxsentan
| Matrix: | Human Plasma |
| Assay Range: | 5 - 5,000 ng/mL 10 - 10,000 ng/mL |
| Sample Volume: | 0.05 mL |
| Anti-Coagulant: | EDTA |
| Storage Temperature (°C): | -20 & -70 |
| Platform: | LC-MS/MS |
| Site: | QPS-Delaware |
| CLIA: | No |
| Therapy Area: | Cardiovascular |
| Classification: | Drugs |
Bosutinib
| Matrix: | Human Plasma |
| Assay Range: | 0.2 - 60 ng/mL |
| Sample Volume: | 0.3 mL |
| Anti-Coagulant: | EDTA |
| Storage Temperature (°C): | -20 & -70 |
| Platform: | LC-MS/MS |
| Site: | QPS-India |
| CLIA: | No |
| Therapy Area: | Oncology |
| Classification: | Drugs |
Links to Relevant Documents
Testimonials
Thanks for the good news, I’m happy to see that within less than a month you will have developed and validated the assay. Good Job!
QPS CLIENT